Gastroenterology Review
eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
1/2026
vol. 21
 
Share:
Send email
Share:
abstract:
Original paper

The potential role of serum miR-182-5p and miR-127-5p in diagnosis of metabolic dysfunction-associated steatotic liver disease and its relationship with insulin resistance

Tarek I. Ahmed
1
,
Esraa A. Mahmoud
2
,
Naglaa R. Ismael
2
,
Omayma O. Abdelaleem
3
,
Nada F. Hemeda
4
,
Heba A. El-Dash
2
,
Abeer A. Khalifa
5
,
Ragab A. Ali
1

  1. Department of Internal Medicine, Faculty of Medicine, Fayoum University, Fayoum, Egypt
  2. Department of Zoology, Faculty of Science, Fayoum University, Fayoum, Egypt
  3. Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Fayoum University, Fayoum, Egypt
  4. Department of Genetics, Faculty of Agriculture, Fayoum University, Fayoum, Egypt
  5. Department of Physiology, Faculty of Medicine, Zagazig University, Egypt
Gastroenterology Rev 2026; 21 (1): 73–81
DOI: https://doi.org/10.5114/pg.2026.160545
Online publish date: 2026/03/27
View full text Get citation
 
PlumX metrics:
Introduction
The most widespread chronic hepatic illness nowadays is metabolic dysfunction-associated steatotic liver disease (MASLD), which has a higher risk of several complications including progression to metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, and hepatocellular carcinoma (HCC). New clinical research has established that microRNAs (miRNAs) are causative factors in the progression of MASLD, which could be used as diagnostic biomarkers and help in producing new treatment modalities.

Material and methods
Sixty adult patients with MASLD and 50 healthy individuals were incorporated in the current work. Serum miR-182-5p and miR-127-5p expression levels were measured using quantitative real-time polymerase chain reaction (RT-PCR).

Results
Compared to healthy controls, patients with MASLD exhibited significantly downregulated serum levels of miR-182-5p and miR-127-5p (p < 0.001). Also, significant negative correlations were observed between miR-182-5p and miR-127-5p with the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) (r = –0.304; p = 0.022, and r = –0.299; p = 0.028, respectively) indicating their association with insulin resistance, which is considered one of the hallmarks of MASLD. Serum miR-182-5p and miR-127-5p levels as predictive biomarkers for MASLD were evaluated using receiver operating characteristic (ROC) analysis.

Conclusions
miR-182-5p and miR-127-5p could serve as novel biomarkers for MASLD diagnosis and may offer a novel approach for the disease’s therapy.

keywords:

metabolic dysfunction-associated steatotic liver disease, miR-182-5p, miR-127-5p, HOMA IR



Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2026 Termedia Sp. z o.o.
Developed by Termedia.